Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will...
First Excimer Platform Approved in Nearly Two Decades Offers Accuracy, Efficiency and Usability Advantages Bausch + Lomb Corporation (NYSE/TSX:...
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today...
Revenues of $1.007 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $84 Million Adjusted EBITDA (non-GAAP)1 of $187 Million...
Presentations Will Feature Studies Evaluating MIEBO™ (Perfluorohexyloctane Ophthalmic Solution), IC-8® Apthera™ IOL and ARMOR Surveillance Study...
Presentations Will Feature Blink® Triple Care Lubricating Dry Eye Drops, MIEBO™ (perfluorohexyloctane ophthalmic solution) and Bausch + Lomb...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.